Stifel Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $45
Stifel Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $45
Stifel 以購買評級啟動礦物質治療藥物的覆蓋範圍,宣布目標價格為 45 美元
Stifel analyst Annabel Samimy initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $45.
斯蒂菲爾分析師安娜貝爾·薩米米(Annabel Samimy)以「買入」評級啟動了 Mineralys 治療藥物(NASDAQ:MLYS)的報導,並宣布目標價格為 45 美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。